Controlled Fluid Removal in Critical Ill Patients With Fluid... | Clinical Trial | StuddyBuddy@endsection Controlled Fluid Removal in Critical Ill Patients With Fluid Overload in the Intensive Care Unit.
Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT04180397

Controlled Fluid Removal in Critical Ill Patients With Fluid Overload in the Intensive Care Unit.

Conditions: Fluid Overload

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE4
Enrollment: 1000
Sponsor: Morten H. Bestle

Location: Department of Intensive Care, Liverpool Hospital Sydney

Summary

This study evaluates the benefits and harms of goal directed fluid removal with furosemide versus placebo in critical ill adult patients with fluid overload in the intensive care unit. Half of the patients will receive furosemide and the other half placebo. The treatment will continue until the excess fluid is excreted.

Eligibility Criteria

Inclusion Criteria: ALL below must be met. * Acute admission to the intensive care unit. * Age ≥ 18 years of age * Fluid overload ≥ 5% of ideal body weight. If possible, all fluids administered before admission to the intensive care unit are to be included in the calculation of cumulative fluid balance. * Clinical stable (minimum criteria: MAP \> 50 mmHg and maximum infusion of 20 microgram/kg/minute of noradrenaline and lactate \< 4.0 mmol/L) Exclusion Criteria: * Known allergy to furosemide or sulphonamides. * Known pre-hospitalization advanced chronic kidney disease (eGFR \< 30 mL/minute/1.73 m\^2 or chronic RRT). * Ongoing renal replacement therapy. * Anuria \> 6 hours. * Rhabdomyolysis with indication for forced diuresis * Ongoing life-threatening bleeding as these patients need specific fluid/blood product strategies. * Acute burn injury of more than 10% of the body surface area as these patients need a specific fluid strategy. * Severe dysnatremia (p-Na \< 120 or \> 155 mmol/L) as these patients need a specific fluid strategy. * Severe hepatic failure as per the clinical team. * Patients undergoing forced treatment. * Fertile women (women \< 50 years) with positive urine human chorionic gonadotropin (hCG) or plasma-hCG. * Consent not obtainable as per the model approved for the specific trial site.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT04180397). StuddyBuddy aggregates publicly available trial information.